JP2020503871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503871A5 JP2020503871A5 JP2019537074A JP2019537074A JP2020503871A5 JP 2020503871 A5 JP2020503871 A5 JP 2020503871A5 JP 2019537074 A JP2019537074 A JP 2019537074A JP 2019537074 A JP2019537074 A JP 2019537074A JP 2020503871 A5 JP2020503871 A5 JP 2020503871A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- inhibitors
- encoding
- protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 claims description 87
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 239000003112 inhibitor Substances 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 230000037361 pathway Effects 0.000 claims description 27
- 239000000556 agonist Substances 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 14
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 230000003213 activating effect Effects 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 7
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 7
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims description 6
- 241000712079 Measles morbillivirus Species 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000008488 polyadenylation Effects 0.000 claims description 6
- 108010029697 CD40 Ligand Proteins 0.000 claims description 5
- 102100032937 CD40 ligand Human genes 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 5
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims description 5
- 101150027249 RL1 gene Proteins 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 241001559185 Mammalian rubulavirus 5 Species 0.000 claims description 4
- 241000713821 Mason-Pfizer monkey virus Species 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 108091006086 inhibitor proteins Proteins 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 244000309459 oncolytic virus Species 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 108010062802 CD66 antigens Proteins 0.000 claims description 3
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 3
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 claims description 3
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 claims description 3
- 206010064571 Gene mutation Diseases 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 3
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 3
- 102100034980 ICOS ligand Human genes 0.000 claims description 3
- 101710093458 ICOS ligand Proteins 0.000 claims description 3
- 102000017578 LAG3 Human genes 0.000 claims description 3
- 101150030213 Lag3 gene Proteins 0.000 claims description 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 3
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 3
- 102000004473 OX40 Ligand Human genes 0.000 claims description 3
- 108010042215 OX40 Ligand Proteins 0.000 claims description 3
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 3
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 3
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 3
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 108010046080 CD27 Ligand Proteins 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 108010017987 CD30 Ligand Proteins 0.000 claims description 2
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 2
- 108091006027 G proteins Proteins 0.000 claims description 2
- 102000030782 GTP binding Human genes 0.000 claims description 2
- 108091000058 GTP-Binding Proteins 0.000 claims description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 101710169105 Minor spike protein Proteins 0.000 claims description 2
- 101710081079 Minor spike protein H Proteins 0.000 claims description 2
- 101800001693 R-peptide Proteins 0.000 claims description 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 2
- 101150085955 US11 gene Proteins 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108700014844 flt3 ligand Proteins 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000015788 innate immune response Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 241000714177 Murine leukemia virus Species 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000007699 co-inhibitory pathway Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024050685A JP2024095709A (ja) | 2017-01-09 | 2024-03-27 | 改変ウイルス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1700350.0 | 2017-01-09 | ||
| GBGB1700350.0A GB201700350D0 (en) | 2017-01-09 | 2017-01-09 | Altered virus |
| PCT/GB2018/050048 WO2018127713A1 (en) | 2017-01-09 | 2018-01-09 | Altered virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024050685A Division JP2024095709A (ja) | 2017-01-09 | 2024-03-27 | 改変ウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503871A JP2020503871A (ja) | 2020-02-06 |
| JP2020503871A5 true JP2020503871A5 (enExample) | 2021-01-28 |
| JP7520511B2 JP7520511B2 (ja) | 2024-07-23 |
Family
ID=58463943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537074A Active JP7520511B2 (ja) | 2017-01-09 | 2018-01-09 | 改変ウイルス |
| JP2024050685A Pending JP2024095709A (ja) | 2017-01-09 | 2024-03-27 | 改変ウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024050685A Pending JP2024095709A (ja) | 2017-01-09 | 2024-03-27 | 改変ウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12059444B2 (enExample) |
| EP (1) | EP3565568B1 (enExample) |
| JP (2) | JP7520511B2 (enExample) |
| KR (1) | KR20190104055A (enExample) |
| CN (1) | CN110198724B (enExample) |
| AU (1) | AU2018205763B2 (enExample) |
| BR (1) | BR112019013215A2 (enExample) |
| CA (1) | CA3049496A1 (enExample) |
| DK (1) | DK3565568T3 (enExample) |
| ES (1) | ES3038026T3 (enExample) |
| GB (1) | GB201700350D0 (enExample) |
| IL (1) | IL267949B2 (enExample) |
| MX (2) | MX2019008146A (enExample) |
| WO (1) | WO2018127713A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3400290T5 (da) | 2016-01-08 | 2024-09-23 | Replimune Ltd | Onkolytisk virusstamme |
| EP4089166A1 (en) | 2016-01-27 | 2022-11-16 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| EP4063859A1 (en) | 2017-04-28 | 2022-09-28 | Merck Sharp & Dohme Corp. | Biomarkers for cancer therapeutics |
| KR20200042904A (ko) | 2017-07-26 | 2020-04-24 | 온코루스, 인크. | 종양용해성 바이러스 벡터 및 그의 용도 |
| CA3071376A1 (en) | 2017-08-03 | 2019-02-07 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
| EP3679040B1 (en) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| AU2019207895A1 (en) | 2018-01-12 | 2020-06-18 | Amgen Inc. | Anti-PD-1 antibodies and methods of treatment |
| CN109762068A (zh) * | 2018-08-09 | 2019-05-17 | 源道隆（苏州）医学科技有限公司 | 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用 |
| MX2021007639A (es) | 2018-12-27 | 2021-08-11 | Amgen Inc | Formulaciones de virus liofilizadas. |
| KR20210135532A (ko) | 2019-03-05 | 2021-11-15 | 암젠 인크 | 암 치료를 위한 종양 용해 바이러스의 용도 |
| TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
| WO2020228828A1 (zh) * | 2019-05-15 | 2020-11-19 | 郑州威瑞生物技术有限公司 | 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法 |
| US20220162644A1 (en) * | 2019-05-29 | 2022-05-26 | Orbis Health Solutions, Llc | Delivery vectors and particles for expressing chimeric receptors and methods of using the same |
| CN110218707B (zh) * | 2019-05-29 | 2021-10-22 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
| IL290495A (en) * | 2019-08-16 | 2022-07-01 | Immvira Co Ltd | Pharmaceutical compositions comprising oncolytic herpes simplex virus for systemic administration |
| CN110982795B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种单纯疱疹病毒及其用途 |
| CN110982794B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种修饰的单纯疱疹病毒 |
| CN114075574A (zh) * | 2020-08-19 | 2022-02-22 | 广东东阳光药业有限公司 | 构建体、溶瘤病毒及其应用 |
| WO2024134495A1 (en) * | 2022-12-20 | 2024-06-27 | Janssen Biotech, Inc. | Oncolytic virus and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5698531A (en) | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
| US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| US6040169A (en) | 1991-01-31 | 2000-03-21 | Medical Research Council | Herpes simplex virus-1 deletion variants and vaccines thereof |
| EP0675961B1 (en) | 1992-03-31 | 2002-11-27 | Arch Development Corporation | Treatment of tumorigenic disease with a modified HSV |
| US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| WO1997012623A1 (en) | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| GB9700411D0 (en) * | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| MXPA02004736A (es) | 1999-11-12 | 2003-01-28 | Oncolytics Biotech Inc | Virus para el tratamiento de trastornos proliferativos celulares. |
| KR100802403B1 (ko) | 2000-01-21 | 2008-02-13 | 바이오벡스 리미티드 | 바이러스 주 |
| JP4212897B2 (ja) | 2001-03-27 | 2009-01-21 | 具紀 藤堂 | ウイルスおよび治療法におけるそれらの使用 |
| GB0317511D0 (en) | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| BRPI0515735A2 (pt) | 2004-11-04 | 2011-10-11 | Pfizer Prod Inc | tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos |
| DK1865986T3 (en) | 2005-03-08 | 2016-04-11 | Pfizer Prod Inc | The anti-CTLA-4 antibody compositions |
| US8986672B2 (en) | 2005-06-23 | 2015-03-24 | The University Of Houston | Use of mutant Herpes Simplex Virus-2 for cancer therapy |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| JP2012504959A (ja) | 2008-10-08 | 2012-03-01 | イントレキソン コーポレーション | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| AU2010321773A1 (en) | 2009-11-20 | 2012-06-14 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| WO2011119925A2 (en) | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| WO2011118866A1 (ko) | 2010-03-26 | 2011-09-29 | 연세대학교 산학협력단 | 네트워크를 통한 심사요청 방법 |
| EP2619312A1 (en) | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| EP2806883B1 (en) | 2012-01-25 | 2019-04-24 | DNAtrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| EP2879498A4 (en) * | 2012-07-30 | 2016-03-30 | Alex Wah Hin Yeung | BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM |
| AU2013308595C1 (en) | 2012-08-30 | 2019-01-17 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
| WO2014066532A1 (en) | 2012-10-23 | 2014-05-01 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| CN104994879A (zh) | 2013-02-22 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 治疗癌症和预防药物抗性的方法 |
| MD4655C1 (ro) | 2013-03-14 | 2020-06-30 | Icahn School Of Medicine At Mount Sinai | Virusurile bolii de Newcastle şi utilizarea acestora |
| TR201902073T4 (tr) | 2013-09-03 | 2019-03-21 | Medimmune Ltd | Bir atenüe Newcastle hastalığı virüsü sağlayan bileşimler ve neoplaziyi tedavi etmek için kullanım yöntemleri. |
| TR201802728T4 (tr) * | 2013-10-25 | 2018-03-21 | Psioxus Therapeutics Ltd | Heterolog genlerle donatılmış onkolitik adenovirüsler. |
| JP6588024B2 (ja) * | 2013-10-28 | 2019-10-09 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 腫瘍溶解性ｈｓｖベクター |
| CA2931322A1 (en) | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| US10933106B2 (en) * | 2014-02-25 | 2021-03-02 | Deutsches Krebsforschungszentrum | RNA viruses for immunovirotherapy |
| MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| JP6895374B2 (ja) * | 2014-07-16 | 2021-06-30 | トランジェーヌＴｒａｎｓｇｅｎｅ | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| JP6843736B2 (ja) | 2014-07-16 | 2021-03-17 | トランジェーヌＴｒａｎｓｇｅｎｅ | 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ |
| US20160040186A1 (en) * | 2014-08-07 | 2016-02-11 | Xiaoyun Liu | Dna construct and method for transgene expression |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| US10525557B2 (en) | 2015-01-23 | 2020-01-07 | Dreamwell, Ltd. | Automated mattress manufacturing process and apparatus |
| CN104987421A (zh) * | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
| DK3400290T5 (da) * | 2016-01-08 | 2024-09-23 | Replimune Ltd | Onkolytisk virusstamme |
| EP3380621A4 (en) * | 2016-04-22 | 2019-05-08 | Immvira Co., Limited | CONSTRUCTION OF THE VECTOR OF OBLIGATES ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CANCER THERAPY CONSTRUCTIONS |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| US20210252135A1 (en) * | 2018-06-21 | 2021-08-19 | Replimune Limited | Treatment using oncolytic virus |
-
2017
- 2017-01-09 GB GBGB1700350.0A patent/GB201700350D0/en not_active Ceased
-
2018
- 2018-01-09 DK DK18701924.5T patent/DK3565568T3/da active
- 2018-01-09 IL IL267949A patent/IL267949B2/en unknown
- 2018-01-09 WO PCT/GB2018/050048 patent/WO2018127713A1/en not_active Ceased
- 2018-01-09 KR KR1020197023554A patent/KR20190104055A/ko not_active Ceased
- 2018-01-09 EP EP18701924.5A patent/EP3565568B1/en active Active
- 2018-01-09 CN CN201880006355.8A patent/CN110198724B/zh active Active
- 2018-01-09 US US16/466,612 patent/US12059444B2/en active Active
- 2018-01-09 JP JP2019537074A patent/JP7520511B2/ja active Active
- 2018-01-09 BR BR112019013215-5A patent/BR112019013215A2/pt unknown
- 2018-01-09 CA CA3049496A patent/CA3049496A1/en active Pending
- 2018-01-09 ES ES18701924T patent/ES3038026T3/es active Active
- 2018-01-09 MX MX2019008146A patent/MX2019008146A/es unknown
- 2018-01-09 AU AU2018205763A patent/AU2018205763B2/en active Active
-
2019
- 2019-07-05 MX MX2025002735A patent/MX2025002735A/es unknown
-
2024
- 2024-03-27 JP JP2024050685A patent/JP2024095709A/ja active Pending
- 2024-07-10 US US18/769,170 patent/US20240358781A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503871A5 (enExample) | ||
| JP2019501671A5 (enExample) | ||
| JP2019501670A5 (enExample) | ||
| US20240358781A1 (en) | Altered virus | |
| US20230203453A1 (en) | Modified oncolytic virus | |
| JP2019500909A5 (enExample) | ||
| JP2024095709A5 (enExample) | ||
| AU2012322999B2 (en) | Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy | |
| CN112020510B (zh) | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 | |
| US20210252135A1 (en) | Treatment using oncolytic virus | |
| KR20190112263A (ko) | 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물 | |
| JPWO2019243847A5 (enExample) | ||
| US20230270861A1 (en) | Inhibitors of the Artemin Pathway for Treatment of Cancer | |
| US20250121017A1 (en) | Oncolytic virotherapy compositions and methods | |
| HK40045432A (en) | Modified oncolytic virus | |
| HK40042181A (en) | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |